CoChat

Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms

Open access
Schischlik, Fiorella, Jäger, Roland, Rosebrock, Felix, Hug, Eva, Schuster, Michael, Holly, Raimund, Fuchs, Elisabeth, Milosevic Feenstra, Jelena D., Bogner, Edith, Gisslinger, Bettina, Schalling, Martin, Rumi, Elisa, Pietra, Daniela, Fischer, Gottfried, Faé, Ingrid, Vulliard, Loan, Menche, Jörg, Haferlach, Torsten, Meggendorfer, Manja, Stengel, Anna, Bock, Christoph, Cazzola, Mario, Gisslinger, Heinz, Kralovics, Robert · 2019 · Blood
Cited by 78

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Ph-negative myeloproliferative neoplasms (MPNs) are hematological cancers that can be subdivided into entities with distinct clinical features. Somatic mutations in JAK2, CALR, and MPL have been described as drivers of the disease, together with a variable landscape of nondriver mutations. Despite detailed knowledge of disease mechanisms, targeted therapies effective enough to eliminate MPN cells are still missing. In this study of 113 MPN patients, we aimed to comprehensively characterize the mutational landscape of the granulocyte transcriptome using RNA sequencing data and subsequently examine the applicability of immunotherapeutic strategies for MPN patients. Following implementation of customized workflows and data filtering, we identified a total of 13 (12/13 novel) gene fusions, 231 nonsynonymous single nucleotide variants, and 21 insertions and deletions in 106 of 113 patients. We found a high frequency of SF3B1-mutated primary myelofibrosis patients (14%) with distinct 3′ splicing patterns, many of these with a protein-altering potential. Finally, from all mutations detected, we generated a virtual peptide library and used NetMHC to predict 149 unique neoantigens in 62% of MPN patients. Peptides from CALR and MPL mutations provide a rich source of neoantigens as a result of their unique ability to bind many common MHC class I molecules. Finally, we propose that mutations derived from splicing defects present in SF3B1-mutated patients may offer an unexplored neoantigen repertoire in MPNs. We validated 35 predicted peptides to be strong MHC class I binders through direct binding of predicted peptides to MHC proteins in vitro. Our results may serve as a resource for personalized vaccine or adoptive cell–based therapy development.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood.2019000519

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 78

Metadata

Authors
Schischlik, F., Jäger, R., Rosebrock, F., Hug, E., Schuster, M., Holly, R., Fuchs, E., Milosevic Feenstra, J. D., Bogner, E., Gisslinger, B., Schalling, M., Rumi, E., Pietra, D., Fischer, G., Faé, I., Vulliard, L., Menche, J., Haferlach, T., Meggendorfer, M., Stengel, A., Bock, C., Cazzola, M., Gisslinger, H., & Kralovics, R.
Venue
Blood
Published
2019-07-11
Volume
134
Issue
2
Pages
199-210
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2944293062
Cited by
78
References
8
FWCI
5.56
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. https://app.cochat.ai/papers/10.1182/blood.2019000519
The paper
Schischlik, F., Jäger, R., Rosebrock, F., Hug, E., Schuster, M., Holly, R., Fuchs, E., Milosevic Feenstra, J. D., Bogner, E., Gisslinger, B., Schalling, M., Rumi, E., Pietra, D., Fischer, G., Faé, I., Vulliard, L., Menche, J., Haferlach, T., Meggendorfer, M., . . . Kralovics, R. (2019). Mutational landscape of the transcriptome offers putative targets for immunotherapy of myeloproliferative neoplasms. Blood. https://doi.org/10.1182/blood.2019000519

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.